Bahareh (Spring) Behrouz, PhD

Dr. Behrouz is the Co-founder and CEO of Vincere Biosciences, where she leads the development of therapeutics that enhance mitochondrial quality control to slow or halt Parkinson’s disease progression. She also serves as Co-founder and CEO of NeuroInitiative, a computational biology company with patented simulation platforms that accelerate drug discovery. 

Dr. Behrouz’s research has long centered on converging biological pathways in Parkinson’s disease, from her doctoral work at Michigan State University on the selective vulnerability of dopaminergic neurons to her postdoctoral studies at the Mayo Clinic on LRRK2-mediated pathogenesis. She has overseen ambitious discovery and development programs, recruited top scientific talent, and earned recognition including JBJ’s 40 Under 40, One Spark’s top science award, and speaking platforms such as TEDx and the March for Science. These efforts are aimed to yield significant benefits for patients with Parkinson’s disease and other age-related diseases.